{"id":4264,"date":"2026-08-09T14:19:37","date_gmt":"2026-08-09T14:19:37","guid":{"rendered":"https:\/\/smartinvestingschronicle.com\/index.php\/2026\/08\/09\/johnson-johnson-has-increased-its-dividend-for-64-consecutive-years-heres-how-much-10000-invested-in-the-dividend-king-pays-annually\/"},"modified":"2026-08-09T14:19:37","modified_gmt":"2026-08-09T14:19:37","slug":"johnson-johnson-has-increased-its-dividend-for-64-consecutive-years-heres-how-much-10000-invested-in-the-dividend-king-pays-annually","status":"publish","type":"post","link":"https:\/\/smartinvestingschronicle.com\/index.php\/2026\/08\/09\/johnson-johnson-has-increased-its-dividend-for-64-consecutive-years-heres-how-much-10000-invested-in-the-dividend-king-pays-annually\/","title":{"rendered":"Johnson &#038; Johnson Has Increased Its Dividend for 64 Consecutive Years. Here&#8217;s How Much $10,000 Invested in the Dividend King Pays Annually."},"content":{"rendered":"<div>\n<h2>Key Points<\/h2>\n<ul>\n<li>\n<p>Few companies have a longer track record of uninterrupted dividend growth. <\/p>\n<\/li>\n<li>\n<p>This streak is likely to be prolonged well into the foreseeable future. <\/p>\n<\/li>\n<li>\n<p>While still an income stock, Johnson &amp; Johnson is also being priced somewhat like a growth stock.<\/p>\n<\/li>\n<li>10 stocks we like better than Johnson &amp; Johnson \u203a<span id=\"pit-41c6ff5c-ecbc-4fe7-95c9-76eb7c67f7b2\" style=\"display:none\"\/><\/li>\n<\/ul>\n<p>It&#8217;s certainly not the market&#8217;s most exciting stock, and not its highest-yielding one either. If you want reliable dividend growth, though, you&#8217;d be hard-pressed to find a better option than drugmaker <strong>Johnson &amp; Johnson<\/strong> <span class=\"ticker\" data-id=\"204142\">(NYSE: JNJ)<\/span>.<\/p>\n<p>In fact, after 64 straight years of annual dividend increases &#8212; and counting &#8212; only eight other Dividend Kings (companies that have raised their dividends for at least 50 consecutive years) can boast a longer streak of yearly dividend growth.<\/p>\n<p><strong>Missed Nvidia in 2009? This Rare Signal Is Flashing Again.<\/strong> <span>In 2009, a &#8220;Double Down&#8221; signal flashed for a little-known chipmaker called Nvidia.<\/span> For the first time in years, that same &#8220;Total Conviction&#8221; signal is flashing for a company 1\/100th the size of Nvidia. <span style=\"text-decoration: underline;\"><strong>Continue \u00bb<\/strong><\/span><\/p>\n<p><span id=\"pit-521ef187-1fce-4fb1-96ce-7e36cb2762e6\" style=\"display:none\"\/><\/p>\n<p class=\"caption\">Image source: Getty Images.<\/p>\n<p>This track record&#8217;s likely to be extended indefinitely, too. Although drugs come and go with their patent protections and expirations, there are always new ways to reload a pharmaceutical company&#8217;s pipeline and portfolio. Johnson &amp; Johnson, for instance, is aiming for annual oncology drug sales of $50 billion by 2030, making it the biggest name in the cancer treatment business.<\/p>\n<p>In other words, there&#8217;s enough potential on the horizon for income-minded investors to consider a stake in J&amp;J.<\/p>\n<p>To this end, how much dividend income would a $10,000 position in the pharmaceutical powerhouse produce? That would mean around 39 shares at current prices. With a forward-looking dividend yield currently around 2.1%, this holding would generate close to $210 per year.<\/p>\n<p>That&#8217;s not a lot; you could certainly find higher-yielding dividend stocks to buy. It&#8217;s not like Johnson &amp; Johnson&#8217;s recent dividend growth has been explosive either. It has only improved by 67% over the course of the past decade, for an average of about 5.3% per year. Not bad, but hardly thrilling.<\/p>\n<p>Just bear in mind that J&amp;J has become much more than a mere income investment since 2024, when it first made oncology a priority with a string of acquisitions like Shockwave Medical, Intra-Cellular Therapies, Halda Therapeutics, and, most recently, Firefly Bio. All of this dealmaking makes it a bit more of a growth investment. It&#8217;s certainly been acting like one, gaining nearly 80% since the end of 2024.<\/p>\n<h2>Should you buy stock in Johnson &amp; Johnson right now?<\/h2>\n<p>Before you buy stock in Johnson &amp; Johnson, consider this:<\/p>\n<p>The Motley Fool Stock Advisor analyst team just identified what they believe are the <strong>10 best stocks<\/strong> for investors to buy now\u2026 and Johnson &amp; Johnson wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n<p>Consider when <strong>Netflix<\/strong> made this list on December 17, 2004&#8230; if you invested $1,000 at the time of our recommendation, <strong>you\u2019d have $399,832<\/strong>!* Or when <strong>Nvidia<\/strong> made this list on April 15, 2005&#8230; if you invested $1,000 at the time of our recommendation, <strong>you\u2019d have $1,374,595<\/strong>!*<\/p>\n<p>Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 968<span>% \u2014 a market-crushing outperformance compared to 215% for the S&amp;P 500. <strong><span style=\"font-weight: 400;\">Don&#8217;t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/span><\/strong><\/span><\/p>\n<p><strong>See the 10 stocks \u00bb<\/strong><\/p>\n<p class=\"disclaimer\" style=\"font-size: 0.65rem; color: #767676; margin-top: 5px; text-align: left;\">*Stock Advisor returns as of August 9, 2026. <\/p>\n<p><span id=\"pit-4b4f2ab8-9d93-447b-8d1a-b57610bdb989\" style=\"display:none\"\/><\/p>\n<p>James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Johnson &amp; Johnson. The Motley Fool has a disclosure policy.<\/p>\n<p class=\"body__disclaimer\">The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson &amp; Johnson is also being priced somewhat like a growth stock. 10 stocks we like better than Johnson &amp; Johnson \u203a It&#8217;s certainly not [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4204,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-4264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/posts\/4264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/comments?post=4264"}],"version-history":[{"count":0,"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/posts\/4264\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/media\/4204"}],"wp:attachment":[{"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/media?parent=4264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/categories?post=4264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartinvestingschronicle.com\/index.php\/wp-json\/wp\/v2\/tags?post=4264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}